FDA approved Morphine Sulfate Tablets for Acute and Chronic PainFDA approved morphine sulfate tablets for acute and chronic pain.

FDA From the archive Source published March 17, 2008 Summary added June 23, 2026 DOI ↗ Editorial oversight: Dr. Ji-eun Park, MD · Brain, Mind & Pain

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Consider using Morphine Sulfate Tablets only when non-opioid alternatives are inadequate, at the lowest effective dose for the shortest duration.

The FDA has approved Morphine Sulfate Tablets, an opioid agonist, for the management of acute pain in adult and pediatric patients weighing at least 50 kg and chronic pain in adults, when alternative treatments are inadequate. The approval highlights the importance of reserving these tablets for patients who do not respond to or cannot tolerate non-opioid options, given the substantial risks of addiction, abuse, misuse, overdose, and death. Clinicians are advised to prescribe the lowest effective dose for the shortest duration, with many acute pain conditions requiring only a few days of opioid therapy. The label also stresses the need for periodic reassessment of continued opioid use and the risks of respiratory depression, especially during initiation and dose titration.

＋ Clinical Details (Mechanism · Dosing · Trial Data · Warnings)

Mechanism of Action

Morphine Sulfate Tablets are opioid agonists. The exact mechanism is not fully detailed in the label, but morphine acts on mu-opioid receptors in the central nervous system to produce analgesia.

Indication & Patient Population

Morphine Sulfate Tablets are indicated for: - Adult and pediatric patients weighing at least 50 kg with acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. - Adults with chronic pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use: Reserve for patients in whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate.

Dosing & Administration

- Prescribe only by healthcare professionals knowledgeable about opioid use and risk mitigation. - Use the lowest effective dosage for the shortest duration consistent with treatment goals. - Initiate in adults and pediatric patients 50 kg and above: 15 to 30 mg every 4 hours as needed for pain, at the lowest dose necessary. Do not exceed 30 mg as an initial dose in pediatric patients. - Titrate based on individual patient response. - Periodically reassess continued need, adverse reactions, and signs of addiction, abuse, or misuse. - Do not rapidly reduce or abruptly discontinue in physically dependent patients. - Discuss opioid overdose reversal agents with patients/caregivers at initiation and renewal.

Key Clinical Trial Data

Trial data not available in label.

Warnings & Contraindications

- Risks of addiction, abuse, misuse, overdose, and death can occur at any dosage or duration. - Respiratory depression can occur at any time, especially during initiation and dose increases. - Reserve for patients with inadequate response to alternative treatments. - Many acute pain conditions require no more than a few days of opioid analgesic. - Rapid reduction or abrupt discontinuation can cause serious withdrawal symptoms, uncontrolled pain, and suicide.

Place in Therapy

Morphine Sulfate Tablets are reserved for patients with severe pain requiring an opioid when non-opioid alternatives are ineffective, not tolerated, or inadequate. They should be used at the lowest effective dose for the shortest duration, with careful monitoring for adverse effects and misuse.

The FDA has approved morphine sulfate tablets, an opioid painkiller, for managing acute pain in adults and children weighing at least 50 kg, and chronic pain in adults. These tablets are meant for patients who have not found relief from non opioid pain medicines or cannot take them. The approval emphasizes that opioids should be used only when necessary, at the lowest effective dose, and for the shortest time needed. Many acute pain conditions require only a few days of treatment.

This approval does not mean that opioids are safe for all types of pain. Morphine sulfate carries serious risks, including addiction, abuse, misuse, overdose, and death. Doctors are advised to reassess the need for continued opioid use regularly. The risk of breathing problems is especially high when starting the drug or increasing the dose.

For patients, this approval provides another option for severe pain that does not respond to other treatments. However, it is important to understand that opioids are not a first choice for pain. If you are prescribed this medication, talk to your doctor about the risks and benefits. Ask about non opioid alternatives and how to use the drug safely. Never take more than prescribed, and do not share it with others.

What this means for you:

Morphine sulfate is a strong opioid for severe pain when other options fail; use only as directed and discuss risks with your doctor.

Study Details

Study typeFda approval

PublishedMar 2008

View Original Abstract ↓

1 INDICATIONS AND USAGE Morphine Sulfate Tablets are indicated for the management of: • adult and pediatric patients weighing at least 50 kg and above with acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. • adults with chronic pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use : Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy [see Warnings and Precautions ( 5.1 )], reserve opioid analgesics, including Morphine Sulfate Tablets for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Morphine Sulfate Tablets are opioid agonists indicated for the management of: • adults and pediatric patients weighing 50 kg and above with acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. • adults with chronic pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy, reserve opioid analgesics, including Morphine Sulfate Tablets for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. ( 1 , 5.1 )

FDA approved Morphine Sulfate Tablets for Acute and Chronic PainFDA approved morphine sulfate tablets for acute and chronic pain.

Study Details

Intravenous tenecteplase improves functional outcomes but increases hemorrhage risk in non-large vessel occlusion acute ischemic stroke

Tenecteplase improves stroke recovery but increases bleeding risk in late treatment window

Clinical research that matters. Delivered to your inbox.

FDA approved Morphine Sulfate Tablets for Acute and Chronic PainFDA approved morphine sulfate tablets for acute and chronic pain.

Study Details

Intravenous tenecteplase improves functional outcomes but increases hemorrhage risk in non-large vessel occlusion acute ischemic stroke

Tenecteplase improves stroke recovery but increases bleeding risk in late treatment window

Clinical research that matters. Delivered to your inbox.

Related in Neurology

From Other Specialties